Acesion Pharma

Executive Summary

Acesion Pharma is a Danish biotechnology company founded in 2010, dedicated to developing novel small-molecule therapies for atrial fibrillation (AF), the most common cardiac arrhythmia. The company is pioneering a first-in-class mechanism targeting SK ion channels, which play a key role in atrial repolarization. By selectively inhibiting SK channels, Acesion aims to create safer and more effective antiarrhythmic drugs compared to current treatments, which often carry significant side effects. The company's lead program is advancing through preclinical and early clinical development, with a focus on demonstrating efficacy and safety in AF patients. Acesion's innovative approach has attracted interest from the cardiology community and potential partners, positioning it as a promising player in the AF therapeutics space. The company remains private and has not disclosed detailed financials, but its focused pipeline and novel mechanism could lead to significant value inflection points as clinical data emerge.

Upcoming Catalysts (preview)

• Q4 2026Initiation of Phase 1 Clinical Trial for Lead SK Inhibitor60% success
• Q2 2026Presentation of Preclinical Efficacy Data at Major Cardiology Conference80% success
• Q3 2026Series B Financing or Strategic Partnership Announcement50% success